ChromaDex (CDXC) Misses Q3 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 hits record high as rate-hike worries ease
- Oil pares losses after reports Houthis attacked Saudi Aramco refinery
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- Exclusive-Silver Lake in talks to buy Workday, sources say
- Crude Inventory Rose 17.2 Million Barrels Last Week - EIA
- Burry doubles down on Nebius short after stock surges 34% on earnings
- S&P 500 ends higher as CoreWeave results fuel AI optimism
- Home Depot CEO Ted Decker takes medical leave; two executives step in
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
ChromaDex Corporation Reports Third Quarter 2018 Financial Results
November 7, 2018 4:01 PM EST- Third Quarter 2018 Net Revenues Increased by 33% to $8.1 Million -
Third Quarter 2018 Highlights vs. Third Quarter 2017
Net sales up 33%, fueled by growth of TRU NIAGEN®, which increased by 97%;TRU NIAGEN sales at 84% of NIAGEN-related sales, up from 60%Gross profit as a percentage of net sales improved by 580 basis points to 53.7%;Launched TRU NIAGEN PRO (60ct, 300mg per capsule), the highest dose of NR in a single capsule;Earned certification from NSF International Certified for Sport program; andSigned MOU for creation of a... More